1.0M XNAS Volume
XNAS 25 Mar, 2025 4:01 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 34.83 per share. | 19 Mar 2025 | 875 | 329,147 (1%) | 0% | 34.8 | 30,476 | Common Stock |
| R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 34.17 per share. | 19 Mar 2025 | 16,463 | 330,022 (1%) | 0% | 34.2 | 562,541 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 34.17 per share. | 19 Mar 2025 | 5,479 | 108,879 (0%) | 0% | 34.2 | 187,217 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 34.83 per share. | 19 Mar 2025 | 291 | 108,588 (0%) | 0% | 34.8 | 10,136 | Common Stock |
| Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 34.83 per share. | 19 Mar 2025 | 127 | 72,233 (0%) | 0% | 34.8 | 4,423 | Common Stock |
| Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 34.17 per share. | 19 Mar 2025 | 2,388 | 72,360 (0%) | 0% | 34.2 | 81,598 | Common Stock |
| Jeff E. Knight | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 34.83 per share. | 19 Mar 2025 | 361 | 87,491 (0%) | 0% | 34.8 | 12,574 | Common Stock |
| Jeff E. Knight | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 34.17 per share. | 19 Mar 2025 | 6,801 | 87,852 (0%) | 0% | 34.2 | 232,390 | Common Stock |
| Tobin C. Schilke | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 52,000 | 52,000 (0%) | 0% | 0 | Common Stock | |
| Tobin C. Schilke | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| R. Scott Struthers | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 89,000 | 346,485 (1%) | 0% | 0 | Common Stock | |
| R. Scott Struthers | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 313,000 | 313,000 | - | - | Stock Option (Right to Buy) | |
| Stephen F. Betz | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 43,000 | 114,358 (0%) | 0% | 0 | Common Stock | |
| Stephen F. Betz | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Dana Pizzuti | Chief Med and Dev Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Dana Pizzuti | Chief Med and Dev Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 43,000 | 74,748 (0%) | 0% | 0 | Common Stock | |
| Jeff E. Knight | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 43,000 | 94,653 (0%) | 0% | 0 | Common Stock | |
| Jeff E. Knight | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.89 per share. | 03 Feb 2025 | 5,000 | 36,748 (0%) | 0% | 16.9 | 84,450 | Common Stock |
| Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 39.07 per share. | 03 Feb 2025 | 5,000 | 31,748 (0%) | 0% | 39.1 | 195,350 | Common Stock |
| Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2025 | 5,000 | 119,042 | - | - | Stock option (Right to Buy) | |
| Isabel Kalofonos | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.89 per share. | 03 Jan 2025 | 15,000 | 44,248 (0%) | 0% | 16.9 | 253,350 | Common Stock |
| Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 52.09 per share. | 03 Jan 2025 | 15,000 | 29,248 (0%) | 0% | 52.1 | 781,350 | Common Stock |
| Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.64 per share. | 03 Jan 2025 | 2,500 | 31,748 (0%) | 0% | 19.6 | 49,100 | Common Stock |
| Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 124,042 | - | - | Stock option (Right to Buy) | |
| Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 2,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Marc J.S. Wilson | CFO | 31 Dec 2024 | 473 | 111,565 (0%) | 0% | 15.0 | 7,086 | Common Stock | |
| Stephen F. Betz | Chief Scientific Officer | Other type of transaction at price $ 14.98 per share. | 31 Dec 2024 | 451 | 71,358 (0%) | 0% | 15.0 | 6,756 | Common Stock |
| Stephen Betz F. | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.91 per share. | 16 Dec 2024 | 2,331 | 71,358 (0%) | 0% | 1.9 | 4,452 | Common Stock |
| F. Stephen Betz | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2024 | 2,331 | 180,039 | - | - | Stock Option (Right to Buy) | |
| Struthers R. Scott | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 57.57 per share. | 02 Dec 2024 | 10,000 | 100,000 (0%) | 0% | 57.6 | 575,700 | Common Stock |
| Jeff E. Knight | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 56.52 per share. | 22 Nov 2024 | 501 | 51,653 (0%) | 0% | 56.5 | 28,317 | Common Stock |
| Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.89 per share. | 03 Oct 2024 | 14,375 | 42,882 (0%) | 0% | 16.9 | 242,794 | Common Stock |
| Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2024 | 14,375 | 139,042 | - | - | Stock option (Right to Buy) | |
| Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 54.63 per share. | 03 Oct 2024 | 14,375 | 28,507 (0%) | 0% | 54.6 | 785,306 | Common Stock |
| Marc J.S. Wilson | CFO | 26 Sep 2024 | 25,000 | 89,000 | - | - | Stock option (Right to Buy) | ||
| Marc J.S. Wilson | CFO | 26 Sep 2024 | 25,000 | 111,092 (0%) | 0% | 51.1 | 1,277,750 | Common Stock | |
| Marc J.S. Wilson | CFO | 26 Sep 2024 | 25,000 | 136,092 (0%) | 0% | 15.3 | 382,250 | Common Stock | |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 51.50 per share. | 10 Sep 2024 | 1,035 | 68,576 (0%) | 0% | 51.5 | 53,303 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 53.19 per share. | 26 Aug 2024 | 3,000 | 69,611 (0%) | 0% | 53.2 | 159,570 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 47.68 per share. | 12 Aug 2024 | 3,000 | 72,611 (0%) | 0% | 47.7 | 143,040 | Common Stock |
| Marc J.S. Wilson | CFO | 25 Jul 2024 | 19,056 | 0 | - | - | Stock option (Right to Buy) | ||
| Marc J.S. Wilson | CFO | 25 Jul 2024 | 19,056 | 130,148 (0%) | 0% | 9.3 | 176,840 | Common Stock | |
| Marc J.S. Wilson | CFO | 25 Jul 2024 | 19,056 | 111,092 (0%) | 0% | 53.9 | 1,026,737 | Common Stock | |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 53.43 per share. | 25 Jul 2024 | 3,000 | 75,611 (0%) | 0% | 53.4 | 160,290 | Common Stock |
| Marc J.S. Wilson | CFO | 15 Jul 2024 | 25,000 | 136,092 (0%) | 0% | 20.0 | 500,500 | Common Stock | |
| Marc J.S. Wilson | CFO | 15 Jul 2024 | 25,000 | 66,000 | - | - | Stock option (Right to Buy) | ||
| Marc J.S. Wilson | CFO | 15 Jul 2024 | 25,000 | 111,092 (0%) | 0% | 55 | 1,375,000 | Common Stock | |
| Jeff E. Knight | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 55.00 per share. | 15 Jul 2024 | 27,000 | 51,653 (0%) | 0% | 55 | 1,485,000 | Common Stock |
| Jeff E. Knight | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 5,687 | 85,313 | - | - | Stock option (Right to Buy) | |
| Jeff E. Knight | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.02 per share. | 15 Jul 2024 | 2,887 | 72,966 (0%) | 0% | 20.0 | 57,798 | Common Stock |
| Jeff E. Knight | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.98 per share. | 15 Jul 2024 | 17,499 | 70,079 (0%) | 0% | 24.0 | 419,626 | Common Stock |
| Jeff E. Knight | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.64 per share. | 15 Jul 2024 | 5,687 | 78,653 (0%) | 0% | 19.6 | 111,693 | Common Stock |
| Jeff E. Knight | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 2,887 | 20,213 | - | - | Stock option (Right to Buy) | |
| Jeff E. Knight | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 17,499 | 112,501 | - | - | Stock option (Right to Buy) | |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 48.55 per share. | 10 Jul 2024 | 3,000 | 78,611 (0%) | 0% | 48.6 | 145,650 | Common Stock |
| James Hassard | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jul 2024 | 15,000 | 130,000 | - | - | Stock option (Right to Buy) | |
| James Hassard | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 44.08 per share. | 05 Jul 2024 | 15,000 | 29,259 (0%) | 0% | 44.1 | 661,200 | Common Stock |
| James Hassard | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.73 per share. | 05 Jul 2024 | 15,000 | 44,259 (0%) | 0% | 19.7 | 295,950 | Common Stock |
| Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jul 2024 | 14,375 | 153,417 | - | - | Stock option (Right to Buy) | |
| Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 44.87 per share. | 03 Jul 2024 | 14,375 | 28,507 (0%) | 0% | 44.9 | 645,006 | Common Stock |
| Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.89 per share. | 03 Jul 2024 | 14,375 | 42,882 (0%) | 0% | 16.9 | 242,794 | Common Stock |
| Marc J.S. Wilson | CFO | 28 Jun 2024 | 32,129 | 19,056 | - | - | Stock option (Right to Buy) | ||
| Marc J.S. Wilson | CFO | 28 Jun 2024 | 32,129 | 143,221 (0%) | 0% | 9.3 | 298,157 | Common Stock | |
| Marc J.S. Wilson | CFO | 28 Jun 2024 | 32,129 | 111,092 (0%) | 0% | 43.6 | 1,401,146 | Common Stock | |
| Jeff E. Knight | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 44.38 per share. | 26 Jun 2024 | 956 | 52,580 (0%) | 0% | 44.4 | 42,427 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 45.37 per share. | 25 Jun 2024 | 3,000 | 80,643 (0%) | 0% | 45.4 | 136,110 | Common Stock |
| Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.89 per share. | 24 Jun 2024 | 9,500 | 37,286 (0%) | 0% | 16.9 | 160,455 | Common Stock |
| Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2024 | 9,500 | 167,792 | - | - | Stock option (Right to Buy) | |
| Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 45.73 per share. | 24 Jun 2024 | 9,500 | 27,786 (0%) | 0% | 45.7 | 434,435 | Common Stock |
| James Hassard | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.73 per share. | 21 Jun 2024 | 15,000 | 44,259 (0%) | 0% | 19.7 | 295,950 | Common Stock |
| James Hassard | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2024 | 15,000 | 145,000 | - | - | Stock option (Right to Buy) | |
| James Hassard | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 44.66 per share. | 21 Jun 2024 | 15,000 | 29,259 (0%) | 0% | 44.7 | 669,900 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 43.86 per share. | 10 Jun 2024 | 3,000 | 83,643 (0%) | 0% | 43.9 | 131,580 | Common Stock |
| Wendell D. Wierenga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Wendell D. Wierenga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 3,400 | 109,246 (0%) | 0% | 0 | Common Stock | |
| Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 3,400 | 21,936 (0%) | 0% | 0 | Common Stock | |
| Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 3,400 | 9,400 (0%) | 0% | 0 | Common Stock | |
| Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Rogerio Vivaldi Coelho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 3,400 | 14,400 (0%) | 0% | 0 | Common Stock | |
| Rogerio Vivaldi Coelho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Stephanie S. Okey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 3,400 | 9,400 (0%) | 0% | 0 | Common Stock | |
| Stephanie S. Okey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Weston Nichols | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 3,400 | 9,400 (0%) | 0% | 0 | Common Stock | |
| Weston Nichols | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Caren Deardorf | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Caren Deardorf | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 3,400 | 9,400 (0%) | 0% | 0 | Common Stock | |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 47.49 per share. | 28 May 2024 | 3,000 | 86,643 (0%) | 0% | 47.5 | 142,470 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 49.43 per share. | 10 May 2024 | 3,000 | 89,643 (0%) | 0% | 49.4 | 148,290 | Common Stock |
| R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.28 per share. | 08 May 2024 | 107,448 | 364,933 (1%) | 0% | 9.3 | 997,117 | Common Stock |
| R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2024 | 107,448 | 16,342 | - | - | Stock Option (Right to Buy) | |
| R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 49.40 per share. | 08 May 2024 | 107,448 | 257,485 (1%) | 0% | 49.4 | 5,307,931 | Common Stock |
| R. Scott Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Apr 2024 | 350 | 257,485 (1%) | 0% | 0 | Common Stock | |
| R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.91 per share. | 15 Apr 2024 | 20,000 | 257,835 (1%) | 0% | 1.9 | 38,200 | Common Stock |
| R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2024 | 20,000 | 81,270 | - | - | Stock Option (Right to Buy) | |
| Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2024 | 14,375 | 177,292 | - | - | Stock option (Right to Buy) | |
| Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 44.47 per share. | 15 Apr 2024 | 14,375 | 27,786 (0%) | 0% | 44.5 | 639,256 | Common Stock |
| Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.89 per share. | 15 Apr 2024 | 14,375 | 42,161 (0%) | 0% | 16.9 | 242,794 | Common Stock |
| R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.28 per share. | 04 Apr 2024 | 40,951 | 278,786 (1%) | 0% | 9.3 | 380,025 | Common Stock |
| R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2024 | 40,951 | 123,790 | - | - | Non-qualified stock option (Right to Buy) | |
| R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 49.17 per share. | 04 Apr 2024 | 40,951 | 237,835 (0%) | 0% | 49.2 | 2,013,561 | Common Stock |
| Stephanie S. Okey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.29 per share. | 28 Mar 2024 | 17,500 | 23,500 (0%) | 0% | 18.3 | 320,075 | Common Stock |
| Stephanie S. Okey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2024 | 17,500 | 0 | - | - | Stock Option (right to buy) | |
| Stephanie S. Okey | Director | Sale of securities on an exchange or to another person at price $ 46.38 per share. | 28 Mar 2024 | 17,500 | 6,000 (0%) | 0% | 46.4 | 811,650 | Common Stock |
| Jeff E. Knight | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.98 per share. | 22 Mar 2024 | 30,000 | 84,939 (0%) | 0% | 24.0 | 719,400 | Common Stock |
| Jeff E. Knight | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Mar 2024 | 30,000 | 130,000 | - | - | Stock Option (right to buy) | |
| Jeff E. Knight | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 45.39 per share. | 22 Mar 2024 | 2,359 | 52,580 (0%) | 0% | 45.4 | 107,075 | Common Stock |
| Jeff E. Knight | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 44.22 per share. | 22 Mar 2024 | 30,000 | 54,939 (0%) | 0% | 44.2 | 1,326,600 | Common Stock |
| Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 43.57 per share. | 20 Mar 2024 | 12,500 | 18,536 (0%) | 0% | 43.6 | 544,625 | Common Stock |
| Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 45.50 per share. | 20 Mar 2024 | 17,500 | 18,536 (0%) | 0% | 45.5 | 796,250 | Common Stock |
| Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.29 per share. | 20 Mar 2024 | 17,500 | 36,036 (0%) | 0% | 18.3 | 320,075 | Common Stock |
| Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 43.58 per share. | 20 Mar 2024 | 17,500 | 18,536 (0%) | 0% | 43.6 | 762,650 | Common Stock |
| Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.23 per share. | 20 Mar 2024 | 17,500 | 36,036 (0%) | 0% | 20.2 | 354,025 | Common Stock |
| Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 43.57 per share. | 20 Mar 2024 | 12,500 | 18,536 (0%) | 0% | 43.6 | 544,625 | Common Stock |
| Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.23 per share. | 20 Mar 2024 | 12,500 | 31,036 (0%) | 0% | 23.2 | 290,375 | Common Stock |
| Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.24 per share. | 20 Mar 2024 | 12,500 | 31,036 (0%) | 0% | 23.2 | 290,500 | Common Stock |
| Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 17,500 | 0 | - | - | Stock Option (right to buy) | |
| Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 17,500 | 0 | - | - | Stock Option (right to buy) | |
| Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 12,500 | 0 | - | - | Stock Option (right to buy) | |
| Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 12,500 | 0 | - | - | Stock Option (right to buy) | |
| Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 10,000 | 191,667 | - | - | Stock Option (right to buy) | |
| Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 4,375 | 201,667 | - | - | Stock Option (right to buy) | |
| Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 43.69 per share. | 20 Mar 2024 | 714 | 27,786 (0%) | 0% | 43.7 | 31,195 | Common Stock |
| Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 43.28 per share. | 20 Mar 2024 | 10,000 | 28,500 (0%) | 0% | 43.3 | 432,800 | Common Stock |
| Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.89 per share. | 20 Mar 2024 | 10,000 | 38,500 (0%) | 0% | 16.9 | 168,900 | Common Stock |
| Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 45.89 per share. | 20 Mar 2024 | 4,375 | 28,500 (0%) | 0% | 45.9 | 200,769 | Common Stock |
| Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.89 per share. | 20 Mar 2024 | 4,375 | 32,875 (0%) | 0% | 16.9 | 73,894 | Common Stock |
| Marc J.S. Wilson | CFO | 18 Mar 2024 | 6,942 | 110,630 (0%) | 0% | 42.9 | 297,881 | Common Stock | |
| Marc J.S. Wilson | CFO | 18 Mar 2024 | 3,983 | 117,572 (0%) | 0% | 38.1 | 151,912 | Common Stock | |
| R. Scott Struthers | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.14 per share. | 18 Mar 2024 | 12,687 | 237,835 (0%) | 0% | 38.1 | 483,882 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.14 per share. | 18 Mar 2024 | 3,655 | 92,643 (0%) | 0% | 38.1 | 139,402 | Common Stock |
| James Hassard | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.14 per share. | 18 Mar 2024 | 1,741 | 29,259 (0%) | 0% | 38.1 | 66,402 | Common Stock |
| Dana Pizzuti | Chief Med and Dev Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.14 per share. | 18 Mar 2024 | 411 | 28,500 (0%) | 0% | 38.1 | 15,676 | Common Stock |
| Jeff E. Knight | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.14 per share. | 18 Mar 2024 | 4,283 | 54,939 (0%) | 0% | 38.1 | 163,354 | Common Stock |
| Marc J.S. Wilson | CFO | 04 Mar 2024 | 25,500 | 121,555 (0%) | 0% | 0 | Common Stock | ||
| Marc J.S. Wilson | CFO | 04 Mar 2024 | 95,500 | 95,500 | - | - | Stock Option (right to buy) | ||
| R. Scott Struthers | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 65,000 | 250,522 (1%) | 0% | 0 | Common Stock | |
| R. Scott Struthers | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 240,000 | 240,000 | - | - | Stock Option (right to buy) | |
| Stephen F. Betz | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 23,000 | 96,298 (0%) | 0% | 0 | Common Stock | |
| Stephen F. Betz | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 87,000 | 87,000 | - | - | Stock Option (right to buy) | |
| James Hassard | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 63,000 | 63,000 | - | - | Stock Option (right to buy) | |
| James Hassard | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 17,000 | 31,000 (0%) | 0% | 0 | Common Stock | |
| Dana Pizzuti | Chief Med and Dev Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 23,000 | 28,911 (0%) | 0% | 0 | Common Stock | |
| Dana Pizzuti | Chief Med and Dev Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 87,000 | 87,000 | - | - | Stock Option (right to buy) | |
| Jeff E. Knight | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 87,000 | 87,000 | - | - | Stock Option (right to buy) | |
| Jeff E. Knight | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 23,000 | 59,222 (0%) | 0% | 0 | Common Stock | |
| Scott Struthers R. | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Feb 2024 | 60,000 | 570,805 (2%) | 0% | 0 | Common Stock | |
| Scott R. Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Feb 2024 | 20,000 | 110,000 (0%) | 0% | 0 | Common Stock | |
| R. Struthers Scott | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Feb 2024 | 20,000 | 110,000 (0%) | 0% | 0 | Common Stock | |
| Struthers Scott R. | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Feb 2024 | 20,000 | 110,000 (0%) | 0% | 0 | Common Stock | |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 37.26 per share. | 25 Jan 2024 | 3,000 | 73,298 (0%) | 0% | 37.3 | 111,780 | Common Stock |
| Stephen Betz F. | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 37.65 per share. | 10 Jan 2024 | 3,000 | 76,298 (0%) | 0% | 37.7 | 112,950 | Common Stock |
| Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.89 per share. | 03 Jan 2024 | 14,375 | 20,286 (0%) | 0% | 16.9 | 242,794 | Common Stock |
| Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 03 Jan 2024 | 14,375 | 5,911 (0%) | 0% | 35 | 503,125 | Common Stock |
| Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2024 | 14,375 | 206,042 | - | - | Non-qualified stock option (Right to Buy) | |
| Wilson Marc J.S. | CFO | 02 Jan 2024 | 10,000 | 51,185 | - | - | Non-qualified stock option (Right to Buy) | ||
| Wilson Marc J.S. | CFO | 02 Jan 2024 | 10,000 | 96,055 (0%) | 0% | 35.5 | 354,700 | Common Stock | |
| Marc Wilson J.S. | CFO | 02 Jan 2024 | 10,000 | 106,055 (0%) | 0% | 9.3 | 92,800 | Common Stock | |
| E. Jeff Knight | Chief Operating Officer | Other type of transaction at price $ 14.98 per share. | 31 Dec 2023 | 931 | 36,222 (0%) | 0% | 15.0 | 13,946 | Common Stock |
| E. Jeff Knight | Chief Operating Officer | Other type of transaction at price $ 14.98 per share. | 31 Dec 2023 | 891 | 35,291 (0%) | 0% | 15.0 | 13,347 | Common Stock |
| F. Betz Stephen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.89 per share. | 26 Dec 2023 | 3,000 | 79,298 (0%) | 0% | 35.9 | 107,670 | Common Stock |
| Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2023 | 9,583 | 220,417 | - | - | Non-qualified stock option (Right to Buy) | |
| Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.89 per share. | 21 Dec 2023 | 9,583 | 15,494 (0%) | 0% | 16.9 | 161,857 | Common Stock |
| Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 34.57 per share. | 21 Dec 2023 | 9,583 | 5,911 (0%) | 0% | 34.6 | 331,284 | Common Stock |
| Betz Stephen F. | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 32.87 per share. | 11 Dec 2023 | 3,000 | 82,298 (0%) | 0% | 32.9 | 98,610 | Common Stock |
| R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2023 | 10,000 | 151,270 | - | - | Incentve stock option (Right to Buy) | |
| R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.91 per share. | 14 Aug 2023 | 10,000 | 135,522 (0%) | 0% | 1.9 | 19,100 | Common Stock |
| R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 20.14 per share. | 11 Jul 2023 | 24,384 | 656,421 (2%) | 0% | 20.1 | 491,094 | Common Stock |
| R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 20.17 per share. | 11 Jul 2023 | 11,459 | 644,962 (2%) | 0% | 20.2 | 231,128 | Common Stock |
| R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 20.35 per share. | 11 Jul 2023 | 14,157 | 630,805 (2%) | 0% | 20.4 | 288,095 | Common Stock |
| Marc J.S. Wilson | CFO | 20 Jun 2023 | 20,000 | 115,158 (0%) | 0% | 9.3 | 185,600 | Common Stock | |
| Marc J.S. Wilson | CFO | 20 Jun 2023 | 20,000 | 71,185 | - | - | Non-qualified stock option (Right to Buy) | ||
| Marc J.S. Wilson | CFO | 20 Jun 2023 | 20,000 | 95,158 (0%) | 0% | 20.0 | 399,400 | Common Stock | |
| Marc J.S. Wilson | CFO | 20 Jun 2023 | 10,922 | 95,158 (0%) | 0% | 20.0 | 218,003 | Common Stock | |
| Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 6,000 | 18,536 (0%) | 0% | 0 | Common Stock | |
| Wendell D. Wierenga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Wendell D. Wierenga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 6,000 | 105,846 (0%) | 0% | 0 | Common Stock | |
| Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 6,000 | 6,000 (0%) | 0% | 0 | Common Stock | |
| Rogerio Vivaldi Coelho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 6,000 | 11,000 (0%) | 0% | 0 | Common Stock | |
| Rogerio Vivaldi Coelho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Stephanie S. Okey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 6,000 | 6,000 (0%) | 0% | 0 | Common Stock | |
| Stephanie S. Okey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 20.81 per share. | 16 Jun 2023 | 50,000 | 680,805 (2%) | 0% | 20.8 | 1,040,500 | Common Stock |
| Weston Nichols | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 6,000 | 6,000 (0%) | 0% | 0 | Common Stock | |
| Weston Nichols | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Caren Deardorf | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 6,000 | 6,000 (0%) | 0% | 0 | Common Stock | |
| Caren Deardorf | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Rogerio Vivaldi Coelho | Director | Purchase of securities on an exchange or from another person at price $ 22.06 per share. | 08 Jun 2023 | 5,000 | 5,000 (0%) | 0% | 22.1 | 110,300 | Common Stock |
| Dana Pizzuti | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.98 per share. | 03 Apr 2023 | 4,288 | 12,712 (0%) | 0% | 16.0 | 68,522 | Common Stock |
| Dana Pizzuti | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 16.15 per share. | 03 Apr 2023 | 8,212 | 4,500 (0%) | 0% | 16.2 | 132,624 | Common Stock |
| Alan Krasner | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.12 per share. | 16 Mar 2023 | 1,687 | 42,301 (0%) | 0% | 17.1 | 28,881 | Common Stock |
| Marc J.S. Wilson | CFO | 16 Mar 2023 | 1,666 | 106,080 (0%) | 0% | 17.1 | 28,522 | Common Stock | |
| R. Scott Struthers | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.12 per share. | 16 Mar 2023 | 4,628 | 125,522 (0%) | 0% | 17.1 | 79,231 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.12 per share. | 16 Mar 2023 | 1,410 | 86,879 (0%) | 0% | 17.1 | 24,139 | Common Stock |
| Jeff E. Knight | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.12 per share. | 16 Mar 2023 | 587 | 34,400 (0%) | 0% | 17.1 | 10,049 | Common Stock |
| Alan Krasner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 19,500 | 43,988 (0%) | 0% | 0 | Common Stock | |
| Alan Krasner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 91,000 | 91,000 | - | - | Common Stock (right to buy) | |
| Marc J.S. Wilson | CFO | 01 Mar 2023 | 112,850 | 112,850 | - | - | Stock Option (right to buy) | ||
| Marc J.S. Wilson | CFO | 01 Mar 2023 | 24,200 | 107,746 (0%) | 0% | 0 | Common Stock | ||
| R. Scott Struthers | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 287,700 | 287,700 | - | - | Common Stock (right to buy) | |
| R. Scott Struthers | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 61,650 | 130,150 (0%) | 0% | 0 | Common Stock | |
| Stephen F. Betz | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 110,000 | 110,000 | - | - | Stock Option (right to buy) | |
| Stephen F. Betz | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 23,600 | 88,289 (0%) | 0% | 0 | Common Stock | |
| James Hassard | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 14,000 | 14,000 (0%) | 0% | 0 | Common Stock | |
| James Hassard | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 65,250 | 65,250 | - | - | Stock Option (right to buy) | |
| Dana Pizzuti | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 4,500 | 17,000 (0%) | 0% | 0 | Common Stock | |
| Dana Pizzuti | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | |
| Jeff E. Knight | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 91,000 | 91,000 | - | - | Stock Option (right to buy) | |
| Jeff E. Knight | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 29,500 | 34,987 (0%) | 0% | 0 | Common Stock | |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 19.59 per share. | 01 Feb 2023 | 3,126 | 64,689 (0%) | 0% | 19.6 | 61,238 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.07 per share. | 25 Jan 2023 | 8,336 | 67,815 (0%) | 0% | 21.1 | 175,640 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 17 Jan 2023 | 3,126 | 76,151 (0%) | 0% | 18 | 56,268 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.35 per share. | 03 Jan 2023 | 3,126 | 79,277 (0%) | 0% | 18.3 | 57,362 | Common Stock |
| Alan Krasner | Chief Medical Officer | Other type of transaction at price $ 11.02 per share. | 31 Dec 2022 | 712 | 24,488 (0%) | 0% | 11.0 | 7,846 | Common Stock |
| Alan Krasner | Chief Medical Officer | Other type of transaction at price $ 11.02 per share. | 31 Dec 2022 | 1,215 | 23,776 (0%) | 0% | 11.0 | 13,389 | Common Stock |
| Marc J.S. Wilson | CFO | 31 Dec 2022 | 482 | 83,546 (0%) | 0% | 11.0 | 5,312 | Common Stock | |
| Marc J.S. Wilson | CFO | 31 Dec 2022 | 1,446 | 83,064 (0%) | 0% | 11.0 | 15,935 | Common Stock | |
| Jeff E. Knight | Chief Operating Officer | Other type of transaction at price $ 15.16 per share. | 31 Dec 2022 | 537 | 5,487 (0%) | 0% | 15.2 | 8,141 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 15 Dec 2022 | 3,126 | 82,403 (0%) | 0% | 16 | 50,016 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 17.84 per share. | 01 Dec 2022 | 3,126 | 84,968 (0%) | 0% | 17.8 | 55,768 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.72 per share. | 15 Nov 2022 | 3,126 | 88,094 (0%) | 0% | 18.7 | 58,519 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.52 per share. | 01 Nov 2022 | 3,126 | 91,220 (0%) | 0% | 18.5 | 57,894 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 17.73 per share. | 17 Oct 2022 | 3,126 | 94,346 (0%) | 0% | 17.7 | 55,424 | Common Stock |
| R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Oct 2022 | 11,100 | 161,270 | - | - | Incentive stock option (Right to Buy) | |
| R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.91 per share. | 12 Oct 2022 | 11,100 | 68,500 (0%) | 0% | 1.9 | 21,201 | Common Stock |
| Dana Pizzuti | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2022 | 12,500 | 12,500 (0%) | 0% | 0 | Common Stock | |
| Dana Pizzuti | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2022 | 230,000 | 230,000 | - | - | Stock Option (right to buy) | |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 19.64 per share. | 03 Oct 2022 | 3,126 | 97,472 (0%) | 0% | 19.6 | 61,395 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.01 per share. | 15 Sep 2022 | 4,168 | 100,598 (0%) | 0% | 21.0 | 87,570 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.00 per share. | 07 Sep 2022 | 1,042 | 104,766 (0%) | 0% | 21.0 | 21,884 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.59 per share. | 01 Sep 2022 | 3,126 | 105,808 (0%) | 0% | 18.6 | 58,112 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Other type of transaction at price $ 11.02 per share. | 01 Sep 2022 | 1,336 | 108,934 (0%) | 0% | 11.0 | 14,723 | Common Stock |
| Jeff E. Knight | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 20.70 per share. | 26 Jul 2022 | 1,152 | 4,950 (0%) | 0% | 20.7 | 23,847 | Common Stock |
| Jeff E. Knight | Chief Operating Officer | Other type of transaction at price $ 17.44 per share. | 26 Jul 2022 | 1,152 | 6,102 (0%) | 0% | 17.4 | 20,091 | Common Stock |
| Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 20.96 per share. | 13 Jul 2022 | 5,700 | 12,536 (0%) | 0% | 21.0 | 119,455 | Common Stock |
| Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 5,700 | 0 | - | - | Non-qualified stock option (Right to Buy) | |
| Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.45 per share. | 13 Jul 2022 | 5,700 | 18,236 (0%) | 0% | 1.5 | 8,265 | Common Stock |
| Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Wendell D. Wierenga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Rogerio Vivaldi Coelho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 8,750 | 8,750 | - | - | Stock Option (right to buy) | |
| Stephanie S. Okey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Weston Nichols | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Caren Deardorf | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 4,375 | 4,375 | - | - | Stock Option (right to buy) | |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.10 per share. | 02 May 2022 | 3,247 | 107,598 (0%) | 0% | 20.1 | 65,252 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.81 per share. | 18 Apr 2022 | 5,664 | 110,845 (0%) | 0% | 25.8 | 146,188 | Common Stock |
| R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 25.42 per share. | 13 Apr 2022 | 24,674 | 844,774 (3%) | 0% | 25.4 | 627,329 | Common Stock |
| R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 26.52 per share. | 13 Apr 2022 | 44,793 | 799,981 (3%) | 0% | 26.5 | 1,188,040 | Common Stock |
| R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 27.53 per share. | 13 Apr 2022 | 69,176 | 730,805 (3%) | 0% | 27.5 | 1,904,256 | Common Stock |
| R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 25.34 per share. | 05 Apr 2022 | 21,357 | 869,448 (3%) | 0% | 25.3 | 541,225 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 23.97 per share. | 04 Apr 2022 | 9,000 | 116,509 (0%) | 0% | 24.0 | 215,762 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.06 per share. | 31 Mar 2022 | 4,164 | 129,673 (0%) | 0% | 21.1 | 87,700 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.80 per share. | 31 Mar 2022 | 4,164 | 125,509 (0%) | 0% | 21.8 | 90,775 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.94 per share. | 15 Mar 2022 | 3,123 | 133,837 (0%) | 0% | 18.9 | 59,150 | Common Stock |
| Caren Deardorf | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2022 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| James Hassard | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 160,000 | 160,000 | - | - | Stock Option (right to buy) | |
| Alan Krasner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 14,250 | 22,561 (0%) | 0% | 0 | Common Stock | |
| Alan Krasner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 66,500 | 66,500 | - | - | Common Stock (right to buy) | |
| Marc J.S. Wilson | CFO | 28 Feb 2022 | 91,000 | 91,000 | - | - | Stock Option (right to buy) | ||
| Marc J.S. Wilson | CFO | 28 Feb 2022 | 19,500 | 81,618 (0%) | 0% | 0 | Common Stock | ||
| R. Scott Struthers | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 249,200 | 249,200 | - | - | Common Stock (right to buy) | |
| R. Scott Struthers | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 53,400 | 57,400 (0%) | 0% | 0 | Common Stock | |
| Stephen F. Betz | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 16,500 | 140,083 (0%) | 0% | 0 | Common Stock | |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 19.73 per share. | 28 Feb 2022 | 3,123 | 136,960 (0%) | 0% | 19.7 | 61,617 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 77,000 | 77,000 | - | - | Stock Option (right to buy) | |
| Ajay Madan | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 19.88 per share. | 28 Feb 2022 | 9,000 | 176,995 (0%) | 0% | 19.9 | 178,920 | Common Stock |
| Ajay Madan | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 65,400 | 65,400 | - | - | Common Stock (right to buy) | |
| Ajay Madan | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 13,950 | 185,995 (0%) | 0% | 0 | Common Stock | |
| Jeff E. Knight | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 23,100 | 23,100 | - | - | Stock Option (right to buy) | |
| Jeff E. Knight | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 4,950 | 4,950 (0%) | 0% | 0 | Common Stock | |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.64 per share. | 15 Feb 2022 | 3,123 | 123,583 (0%) | 0% | 18.6 | 58,213 | Common stock |
| Ajay Madan | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 17.83 per share. | 07 Feb 2022 | 13,411 | 172,045 (0%) | 0% | 17.8 | 239,085 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.79 per share. | 01 Feb 2022 | 3,123 | 126,706 (0%) | 0% | 18.8 | 58,681 | Common stock |
| Alan Krasner | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 21.21 per share. | 19 Jan 2022 | 6,700 | 8,311 (0%) | 0% | 21.2 | 142,080 | Common Stock |
| Alan Krasner | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2022 | 6,700 | 160,473 | - | - | Non-qualified stock option (Right to Buy) | |
| Alan Krasner | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.01 per share. | 19 Jan 2022 | 6,700 | 15,011 (0%) | 0% | 12.0 | 80,467 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 23.29 per share. | 18 Jan 2022 | 4,168 | 128,875 (0%) | 0% | 23.3 | 97,073 | Common stock |
| Rogerio Vivaldi Coelho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 28.02 per share. | 03 Jan 2022 | 7,168 | 133,043 (0%) | 0% | 28.0 | 200,847 | Common stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 27.95 per share. | 28 Dec 2021 | 3,000 | 140,211 (0%) | 0% | 28.0 | 83,852 | Common stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 24.14 per share. | 15 Dec 2021 | 5,668 | 143,211 (0%) | 0% | 24.1 | 136,826 | Common stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 27.38 per share. | 01 Dec 2021 | 5,668 | 148,879 (0%) | 0% | 27.4 | 155,190 | Common stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 27.97 per share. | 15 Nov 2021 | 1,500 | 154,547 (0%) | 0% | 28.0 | 41,955 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 26.75 per share. | 15 Nov 2021 | 5,668 | 156,047 (0%) | 0% | 26.8 | 151,619 | Common stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 27.95 per share. | 05 Nov 2021 | 12,600 | 165,615 (0%) | 0% | 28.0 | 352,195 | Common stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 28.42 per share. | 05 Nov 2021 | 3,900 | 161,715 (0%) | 0% | 28.4 | 110,846 | Common stock |
| Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 25.50 per share. | 01 Nov 2021 | 8,954 | 12,536 (0%) | 0% | 25.5 | 228,327 | Common Stock |
| Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.91 per share. | 01 Nov 2021 | 8,954 | 21,490 (0%) | 0% | 1.9 | 17,102 | Common Stock |
| Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 8,954 | 12,092 | - | - | Non-qualified stock option (Right to Buy) | |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 24.79 per share. | 01 Nov 2021 | 5,668 | 178,215 (0%) | 0% | 24.8 | 140,510 | Common stock |
| Ajay Madan | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2021 | 106,383 | 0 | - | - | Stock Option (right to buy) | |
| Ajay Madan | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.73 per share. | 28 Oct 2021 | 106,383 | 184,671 (0%) | 0% | 0.7 | 77,660 | Common Stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 24.00 per share. | 27 Oct 2021 | 3,000 | 183,883 (0%) | 0% | 24.0 | 71,991 | Common stock |
| Stephen F. Betz | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.10 per share. | 21 Oct 2021 | 1,042 | 186,883 (0%) | 0% | 21.1 | 21,984 | Common stock |
| Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.91 per share. | 08 Sep 2021 | 6,046 | 18,582 (0%) | 0% | 1.9 | 11,548 | Common Stock |
| Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 25.50 per share. | 08 Sep 2021 | 6,046 | 12,536 (0%) | 0% | 25.5 | 154,173 | Common Stock |
| Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Sep 2021 | 6,046 | 21,046 | - | - | Non-qualified stock option (Right to Buy) | |
| R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 07 Sep 2021 | 10,000 | 90,000 (0%) | 0% | 25 | 250,000 | Common stock |
| R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 07 Sep 2021 | 10,000 | 90,000 (0%) | 0% | 25 | 250,000 | Common stock |
| R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 07 Sep 2021 | 10,000 | 90,000 (0%) | 0% | 25 | 250,000 | Common stock |
| Jeff E. Knight | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2021 | 160,000 | 160,000 | - | - | Stock Option (right to buy) | |
| Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 19.59 per share. | 26 Jul 2021 | 5,000 | 12,536 (0%) | 0% | 19.6 | 97,950 | Common Stock |
| Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jul 2021 | 5,000 | 27,092 | - | - | Non-qualified stock option (Right to Buy) | |
| Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.91 per share. | 26 Jul 2021 | 5,000 | 17,536 (0%) | 0% | 1.9 | 9,550 | Common Stock |
| Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 19.50 per share. | 19 Jul 2021 | 5,000 | 12,536 (0%) | 0% | 19.5 | 97,500 | Common Stock |
| Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2021 | 5,000 | 32,092 | - | - | Non-qualified stock option (Right to Buy) | |
| Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.91 per share. | 19 Jul 2021 | 5,000 | 17,536 (0%) | 0% | 1.9 | 9,550 | Common Stock |
| Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2021 | 5,000 | 37,092 | - | - | Non-qualified stock option (Right to Buy) | |
| Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 20.71 per share. | 12 Jul 2021 | 5,000 | 12,536 (0%) | 0% | 20.7 | 103,550 | Common Stock |
| Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.91 per share. | 12 Jul 2021 | 5,000 | 17,536 (0%) | 0% | 1.9 | 9,550 | Common Stock |
| Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Wendell D. Wierenga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Stephanie S. Okey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Weston Nichols | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Alan Krasner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
| Marc J.S. Wilson | CFO and Secretary | 26 Feb 2021 | 114,000 | 114,000 | - | - | Stock Option (right to buy) | ||
| R. Scott Struthers | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 294,000 | 294,000 | - | - | Stock Option (right to buy) | |
| Ajay Madan | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 131,000 | 131,000 | - | - | Stock Option (right to buy) | |
| R. Scott Struthers | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 12.60 per share. | 02 Dec 2020 | 1,000 | 1,000 (0%) | 0% | 12.6 | 12,600 | Common stock |
| R. Scott Struthers | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 13.10 per share. | 02 Dec 2020 | 4,000 | 4,000 (0%) | 0% | 13.1 | 52,400 | Common stock |
| Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2020 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 14.46 per share. | 15 Jul 2020 | 17,500 | 890,805 (3%) | 0% | 14.5 | 253,108 | Common stock |
| R. Scott Struthers | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 15.30 per share. | 15 Jul 2020 | 17,500 | 908,305 (3%) | 0% | 15.3 | 267,722 | Common stock |
| Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2020 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Wendell D. Wierenga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2020 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Stephen Kaldor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2020 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Stephanie S. Okey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2020 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Weston Nichols | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2020 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Wendell D. Wierenga | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.73 per share. | 28 Apr 2020 | 25,329 | 99,846 (0%) | 0% | 0.7 | 18,490 | Common Stock |
| Wendell D. Wierenga | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2020 | 25,329 | 12,500 | - | - | Stock Option (right to but) | |
| Alan Krasner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2020 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Marc J.S. Wilson | CFO and Secretary | 24 Feb 2020 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | ||
| R. Scott Struthers | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2020 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Alan Krasner | Chief Medical Officer | Other type of transaction at price $ 14.45 per share. | 31 Dec 2019 | 1,471 | 4,941 (0%) | 0% | 14.5 | 21,256 | Common Stock |
| Marc J.S. Wilson | CFO and Secretary | 31 Dec 2019 | 1,471 | 58,792 (0%) | 0% | 14.5 | 21,256 | Common Stock | |
| R. Scott Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2019 | 100,000 | 100,000 (0%) | 0% | 0 | Common Stock | |
| R. Scott Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2019 | 300,000 | 925,805 (3%) | 1% | 0 | Common Stock | |
| R. Scott Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2019 | 100,000 | 100,000 (0%) | 0% | 0 | Common Stock | |
| R. Scott Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2019 | 100,000 | 100,000 (0%) | 0% | 0 | Common Stock | |
| Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.91 per share. | 16 Dec 2019 | 3,500 | 16,036 (0%) | 0% | 1.9 | 6,685 | Common Stock |
| Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2019 | 3,500 | 42,092 | - | - | Non-qualified stock option (Right to Buy) | |
| Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 22.50 per share. | 16 Dec 2019 | 3,500 | 12,536 (0%) | 0% | 22.5 | 78,750 | Common Stock |
| R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.91 per share. | 05 Aug 2019 | 10,000 | 1,225,805 (5%) | 0% | 1.9 | 19,100 | Common Stock |
| R. Scott Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 05 Aug 2019 | 1,215,805 | 0 (0%) | 5% | 0 | Common Stock | |
| R. Scott Struthers | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 05 Aug 2019 | 1,215,805 | 1,215,805 (5%) | 5% | 0 | Common Stock | |
| R. Scott Struthers | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2019 | 10,000 | 172,370 | - | - | Stock Option (right to buy) | |
| Stephanie S. Okey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2019 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2019 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Wendell D. Wierenga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2019 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Stephen Kaldor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2019 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Jack Bech Nielsen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2019 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Weston Nichols | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2019 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Alan Krasner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2019 | 56,250 | 56,250 | - | - | Stock Option (right to buy) | |
| Marc J.S. Wilson | Chief Financial Officer | 08 Mar 2019 | 56,250 | 56,250 | - | - | Stock Option (right to buy) | ||
| R. Scott Struthers | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2019 | 176,250 | 176,250 | - | - | Stock Option (right to buy) | |
| Alan Krasner | Chief Medical Officer | Other type of transaction at price $ 14.45 per share. | 31 Dec 2018 | 1,470 | 3,470 (0%) | 0% | 14.5 | 21,242 | Common Stock |
| Marc J.S. Wilson | See Remarks | 31 Dec 2018 | 1,470 | 57,321 (0%) | 0% | 14.5 | 21,242 | Common Stock | |
| Alan Krasner | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 20 Jul 2018 | 2,000 | 2,000 (0%) | 0% | 17 | 34,000 | Common Stock |